Connect Biopharma Holdings Ltd. has announced new data demonstrating a unique mechanism of action for rademikibart, supporting its best-in-class potential for the treatment of inflammatory diseases. The company is currently recruiting for a Phase 1b study of intravenously-administered rademikibart, with topline results expected in the first quarter of 2026. Recruitment is also ongoing for Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data anticipated in mid-2026. Preliminary data from the ongoing Phase 1b study indicate increases in FEV1 occur significantly faster with intravenous administration compared to subcutaneous administration. Results from these studies will be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623542-en) on January 12, 2026, and is solely responsible for the information contained therein.